Articles with public access mandates - Shannon WestinLearn more
Not available anywhere: 8
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance
LP Cobb, CC Sun, R Iyer, AM Nick, ND Fleming, SN Westin, AK Sood, ...
Gynecologic oncology 158 (3), 653-658, 2020
Mandates: US National Institutes of Health
Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors
GZ Dal Molin, SN Westin, P Msaouel, LM Gomes, A Dickens, RL Coleman
International Journal of Gynecologic Cancer 30 (1), 2020
Mandates: V Foundation, USA
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes
DM Gershenson, CC Sun, SN Westin, M Eyada, LP Cobb, LC Nathan, ...
Gynecologic oncology 165 (3), 560-567, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Endometrial cancer (primer)
M Vicky, H MacKay, I Ray-Coquard, DA Levine, SN Westin, A Daisuke, ...
Nature Reviews: Disease Primers 7 (1), 2021
Mandates: US National Institutes of Health
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
DM Gershenson, LP Cobb, SN Westin, Y Zhang, A Jazaeri, A Malpica, ...
Gynecologic oncology 167 (2), 139-145, 2022
Mandates: US National Institutes of Health
Novel therapeutic approaches and targets for ovarian cancer
RA Previs, GB Mills, SN Westin
The ovary, 547-574, 2019
Mandates: US National Institutes of Health
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study
RL Coleman, W Hu, P Soliman, A Nick, PT Ramirez, SN Westin, ...
Gynecologic oncology 161 (1), 104-112, 2021
Mandates: US National Institutes of Health
Next generation sequencing for gynecologic malignancy: Promise and potential pitfalls
EM Hinchcliff, SN Westin
Gynecologic oncology 163 (2), 217-219, 2021
Mandates: US National Institutes of Health
Available somewhere: 168
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ...
Journal of clinical oncology 30 (8), 777-782, 2012
Mandates: US National Institutes of Health
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
H Liang, LWT Cheung, J Li, Z Ju, S Yu, K Stemke-Hale, T Dogruluk, Y Lu, ...
Genome research 22 (11), 2120-2129, 2012
Mandates: US National Institutes of Health
AKT Inhibition in Solid Tumors With AKT1 Mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251-2259, 2017
Mandates: US National Institutes of Health, Cancer Research UK
Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203
AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ...
Journal of clinical oncology 36 (24), 2538-2544, 2018
Mandates: US National Institutes of Health
Endometrial cancer
V Makker, H MacKay, I Ray-Coquard, DA Levine, SN Westin, D Aoki, ...
Nature reviews Disease primers 7 (1), 88, 2021
Mandates: US National Institutes of Health
PARP inhibitors in the management of ovarian cancer: ASCO guideline
WP Tew, C Lacchetti, A Ellis, K Maxian, S Banerjee, M Bookman, ...
Journal of Clinical Oncology 38 (30), 3468-3493, 2020
Mandates: US National Institutes of Health
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer
PT Soliman, SN Westin, S Dioun, CC Sun, E Euscher, MF Munsell, ...
Gynecologic oncology 146 (2), 234-239, 2017
Mandates: US National Institutes of Health
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome
SN Westin, RA Lacour, DL Urbauer, R Luthra, DC Bodurka, KH Lu, ...
Journal of Clinical Oncology 26 (36), 5965-5971, 2008
Mandates: US National Institutes of Health
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
Mandates: US National Institutes of Health
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ...
Science translational medicine 9 (392), eaal5148, 2017
Mandates: US National Institutes of Health, Susan G. Komen
A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ...
Journal of Clinical Oncology 40 (34), 3952-3964, 2022
Mandates: US National Institutes of Health, Health Research Board, Ireland, National …
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program